Last checked at 17 Dec 2023 15:16
PRESS: GSK looks for deals in China as rebuilds relationship
(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News
GSK Share
Chat
GSK Share
Trades8,855
GSK
Live RNS
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,733.50
Bid:
1,732.50
Ask:
1,733.00
Change:
5.00 (0.29%)
Spread:
0.50 (0.029%)
Open:
1,733.00
High:
1,739.50
Low:
1,724.50
Prev. Close:
1,728.50
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Tuesday tips round-up: GlaxoSmithKline, Pace
Thu, 24th Oct 2013 08:10
GlaxoSmithKline's sales in China tumbled by 60 per cent in the third quarter, the company revealed on Wednesday, halving the country's contribution to Glaxo's total quarterly pharmaceutical sales in emerging markets when compared with year-ago levels. However, this hides the fact that the firm's operating margins continue to improve, R&D costs continued to decrease and that the company as a whole is slimming down. It is also generating a substantial free cash flow, which will fund a 6% increase in the dividend and a £1bn share repurchase. The stock is up 18% this year, against 10% for AstraZeneca and 50% for Bristol Myers Squibb. Yet it continues to trade at a discount to Swiss and US rivals. The China has been a drag on the shares; all the more reason to try and put the matter behind it, the Financial Times's Lex column says. Set-top box technology firm Pace on Wednesday agreed to the purchase of Aurora, which makes kit for broadband suppliers that allows these to provide higher-bandwidth video, data and voice services. It comes after the company eschewed the opportunity to go after Motorola's set-top box division, which in the end fetched a far too rich valuation. The transaction increases the company's product range for cable operators and makes financial sense too. Although the deal will be debt-financed, Pace believes that its strong cash-flow will allow it to reduce debt quickly. Once take in savings from synergies and the transaction price are accounted for the acquisition target's earnings multiple comes in at about eight, while existing management are being given an incentive to stay on. Stock in Pace sells on about 11.5 times' earnings, which still looks attractive enough even after the shares sharp gains year-to date, The Times's Tempus says. Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.AB
More News
15 Dec 2023 17:08
European shares end fifth week higher on rate-cut optimism
Barclays sees first ECB rate cut in April
*Read more15 Dec 2023 16:51
LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools
(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.
Read more15 Dec 2023 16:29
PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg
(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.
Read more12 Dec 2023 10:08
AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal
Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.
Read more12 Dec 2023 08:22
TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine
(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.
Read more12 Dec 2023 07:39
LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI
(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.
Read more12 Dec 2023 07:24
GSK seeks to extend RSV vaccine approval in Japan
(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.
Read more11 Dec 2023 08:28
GSK drug gets EU marketing backing for form of endometrial cancer
(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.
Read more11 Dec 2023 07:41
LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook
(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.
Read more11 Dec 2023 07:23
GSK endometrial cancer treatment gets Europe authorisation
(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.
Read more7 Dec 2023 12:54
THG backer Kelso pushes for demerger to trim "inherent" valuation gap
(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.
Read more5 Dec 2023 10:02
LONDON BROKER RATINGS: Goldman lifts Landsec and British Land
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more27 Nov 2023 09:00
GSK announces positive results from Blenrep phase 3 blood cancer trial
(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.
Read more27 Nov 2023 08:02
GSK receives 'positive' headline results from phase III trial
(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.
Read more